HeartSciences (HSCS) Cash & Equivalents (2022 - 2026)

HeartSciences (HSCS) has reported Cash & Equivalents for 5 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• Quarterly Cash & Equivalents rose 54.55% year-over-year to $1.7 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $1.7 million (up 54.55% YoY) and the FY2026 annual result came in at $1.7 million, up 54.55% from the prior year.
• Cash & Equivalents improved to $1.7 million in Q2 2026 per HSCS's latest filing, from $1.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for HSCS reached as high as $7.1 million in Q1 2024 and fell as low as $100144.0 in Q4 2023.
• A 5-year average of $2.7 million and a median of $2.0 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 96.74% — and 2024, when it soared 3946.29%.
• Year by year, Cash & Equivalents stood at $3.1 million in 2022, then plunged by 96.74% to $100144.0 in 2023, then surged by 3946.29% to $4.1 million in 2024, then sank by 72.9% to $1.1 million in 2025, then jumped by 54.81% to $1.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.7 million, $1.1 million, and $2.0 million for Q2 2026, Q4 2025, and Q4 2025 respectively.